Dr. Hari Goyal had the privilege to work in best of Cancer Centers of India. He started his career in the field of Oncology at Tata Memorial Centre & did the prestigious course of DM from All India Institute of Medical Sciences, New Delhi.He is the head of Oncology unit comprising eminent doctors like Dr. Deepak Singla, Dr. Raman Kain & Dr. Smita B. Choudhury. The team effort gives an edge & advantage to the patients management.His practice has a major influence of teachings of pioneers in oncology, Dr. S.H. Advani, Dr. Vinod Kochupillai & Dr. Lalit Kumar.
Education & Training
MBBS from Sardar Patel Medical College, Bikaner in 1993
MD (Internal Medicine) from SMS Hospital, Jaipur in 1997
DM (Oncology) from AIIMS, New Delhi in 2003
Junior Registrar, Tata Memorial Centre, Mumbai
Professional Diploma in Clinical Research in 2008
Medical Oncology & Haematology, Consultant at Tata Memorial Hospital
Medical Oncology & Haematology, Consultant at Rajiv Gandhi Cancer Hospital
Medical Oncology & Haematology, Consultant at Batra hospital, New Delhi
Medical Oncology & Haematology, Consultant at AIIMS, Delhi
Medical Oncology & Haematology, Consultant at Action Cancer Hospital, New Delhi
Medical Oncology & Haematology, Consultant at BL Kapoor Hospital, New Delhi
Holistic approach towards cancer patients.
Try to give cure, control and care by best possible means.
Research and Publications
Clinical research associate in protocol 94CE 32 .Phase III comparative study of combination treatment with TLC D99 liposomal doxorubicin and cyclophosphamide and doxorubicin in metastatic breast cancer.
A Multicentric, open label phase III clinical trial to evaluate the safety of filgrastim in cancer patients with grade 3 or 4 chemotherapy induced neutropenia.
Organizing secretary, 4th international seminar on psychosocial oncology, new delhi ,april 1999.
TZ-01-002: A Randomized, Double-Blind, Multicentre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in combination with weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2- Positive Metastatic Breast Cancer.
SB3-G31-BC: A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptinu00ae in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting.
A multicentre, randomized, open label, two period, two treatment, two way crossover, comparative bioavailability study at Steady state comparing Capecitabine Extended release Capsule 500mg (Intas Pharmaceuticals Ltd, India) to the reference listed drug Xeloda (Capecitabine 500mg ; Roche Pharmaceuticals) in patients of Breast Cancer under fed cond.
A Phase III randomized, open- label, Multi-center, global study of MEDI4736 alone or in combination with Tremelimumab versus standard of Care in the treatment of First-line recurrent or Metastatic Squamous Cell Head & neck cancer patients.
Member to many personal, professional & social organisations.
Disclaimer: Lyfboat does not provide professional medical opinion on the treatment or diagnosis of a particular ailment. All the offered services and information presented on www.lyfboat.com are only for the purpose of public knowledge and cannot substitute the professional consultation of the physician. Lyfboat strongly advice against copying or cloning of its web content and follows the legal protocols for protection of its intellectual property.